- Lexaria’s animal study could be the first step to developing faster and better acting sildenafil oral formulations
- The most prominent study for Lexaria in 2022 is HYPER-H21-4, investigating patented DehydraTECH(TM)-CBD for hypertension and heart disease
Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced positive findings in an animal study that evaluated DehydraTECH(TM) processing of the phosphodiesterase inhibitor (PDE5 inhibitor) sildenafil as potential use for erectile dysfunction management. A clear trend emerged during the course of the study – a faster and higher overall delivery of sildenafil into the bloodstream (https://cnw.fm/SOjPD).
During the animal study, it was determined that in as little as four minutes after dosing, the DehydraTECH formulation of sildenafil delivered 74% more of the PDE5 inhibitor into the bloodstream on average than the concentration-matched, generic control formulation. Within seven minutes, the DehydraTECH-sildenafil formulation achieved a higher average blood level than the generic control reached at any point during the study.
The most well-known sildenafil product on the market is Viagra(R). The medication is bioavailable orally at approximately 40%, with the most common complaint by consumers that it is slow to act. The findings of Lexaria’s animal study are a first step to developing faster and better acting sildenafil oral formulations.
In addition to this successful study, as well as a pivotal human clinical trial investigating DehydraTECH-processed cannabidiol (“CBD”), the company announced plans for more trials this year, as per its annual letter to shareholders outlining milestones in 2021 and plans and expectations for 2022. “During 2021, we completed research & development (‘R&D’) and validating work equal to or greater than all the combined amount previously completed since 2018! We have conducted studies across broad areas of interest but also concentrated in specific areas where we have had supportive data,” CEO Chris Bunka stated in the letter (https://cnw.fm/YZNMd).
Lexaria’s most significant area of investigation for 2022 is DehydraTECH-processed-CBD for potential hypertension and heart disease treatment and
Bunka explained that starting in April (or sooner), the company will begin the largest-ever hypertension study. “If this study is successful, we feel strongly that it will be highly supportive of our IND filing plan, and we will have a clear path toward designing of Phase 1 and even potentially Phase II FDA-registered clinical studies thereunder. Assuming there are no major delays either in study execution or evaluation, we expect full results from this study sometime in Q3, 2022.”
With all these achievements and plans for further development, the company is positioned to secure an important role in the global drug delivery devices market, an expanding sector expected to reach $31.67 billion by 2027 from an estimated $23.1 billion in 2021 (https://cnw.fm/6kAe5). Key factors driving this growth are the rising geriatric population, coupled with the rise of non-communicable diseases (diabetes, cancer, etc.). This surge has also led to a higher demand for non-invasive drug delivery methods.
For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX
HempWire (HW) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWire (HW) is where HEMP news, content and information converge.
To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.hempwire.com
Do you have a questions or are you interested in working with HW? Ask our Editor
HempWire is part of the InvestorBrandNetwork.